Detection and treatment of pheochromocytomas and paragangliomas: current standing of MIBG scintigraphy and future role of PET imaging
- PMID: 19088695
Detection and treatment of pheochromocytomas and paragangliomas: current standing of MIBG scintigraphy and future role of PET imaging
Abstract
Pheochromocytomas are rare tumors arising from chromaffin cells of adrenal medullary or extra-adrenal paraganglionic tissue. These tumors are characterized by synthesis, storage, metabolism and secretion of catecholamines. Similar to the sympathetic nervous system, pheochromocytomas express cellular norepinephrine transporters (NET) through which catecholamines can enter pheochromocytoma cells to be stored in vesicles. Metaiodobenzylguanidine (MIBG) resemblance to norepinephrine and its good affinity and uptake by NET resulted in its use in pheochromocytoma diagnosis from 1981. Both [(123)I]MIBG and [(131)I]MIBG (lower sensitivity) scintigraphy are used for localization of these tumors. Recent discoveries of different hereditary syndromes associated with pheochromocytomas led to the identification of several and new distinct genotype-phenotype associations. Importantly, with this distinction of clinical phenotypes, MIBG was found to have a different performance in subsets of pheochromocytoma patients. Reduced sensitivity of MIBG scintigraphy in some familial paraganglioma syndromes, malignant disease and extra-adrenal paragangliomas has been found. Therefore, newer compounds, especially for positron emission tomography (PET), such as [(11)C]hydroxyephedrine ([(11)C]HED), [(18)F]fluoro-2-deoxy-D-glucose ([(18)F]FDG), [(18)F]fluoro-dihydroxyphenylalanine ([(18)F] FDOPA) and [(18)F]fluorodopamine ([(18)F]FDA) have emerged and were found to be superior to MIBG in the localization of certain types of pheochromocytoma and paragangliomas. Finally, using [(131)I]MIBG represents an important treatment option in patients with malignant pheochromocytoma, but the development of newer treatment modalities is expected. In this review, we provide the reader with an overview of the current standing of [(123)I]- and [(131)I]MIBG in diagnosis and treatment of pheochromocytoma amongst the newer PET imaging agents.
Similar articles
-
I-131 Metaiodobenzylguanidine Therapy of Pheochromocytoma and Paraganglioma.Semin Nucl Med. 2016 May;46(3):203-14. doi: 10.1053/j.semnuclmed.2016.01.011. Semin Nucl Med. 2016. PMID: 27067501 Review.
-
Semiquantitative 123I-Metaiodobenzylguanidine Scintigraphy to Distinguish Pheochromocytoma and Paraganglioma from Physiologic Adrenal Uptake and Its Correlation with Genotype-Dependent Expression of Catecholamine Transporters.J Nucl Med. 2015 Jun;56(6):839-46. doi: 10.2967/jnumed.115.154815. Epub 2015 Apr 16. J Nucl Med. 2015. PMID: 25883126
-
6-18F-fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to 123I-metaiodobenzyl-guanidine scintigraphy in the detection of extraadrenal and hereditary pheochromocytomas and paragangliomas: correlation with vesicular monoamine transporter expression.J Clin Endocrinol Metab. 2010 Jun;95(6):2800-10. doi: 10.1210/jc.2009-2352. Epub 2010 Apr 6. J Clin Endocrinol Metab. 2010. PMID: 20371665
-
Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma.J Clin Endocrinol Metab. 2009 Dec;94(12):4757-67. doi: 10.1210/jc.2009-1248. Epub 2009 Oct 28. J Clin Endocrinol Metab. 2009. PMID: 19864450 Free PMC article.
-
Imaging of neuroendocrine tumors.Semin Nucl Med. 2006 Jul;36(3):228-47. doi: 10.1053/j.semnuclmed.2006.03.007. Semin Nucl Med. 2006. PMID: 16762613 Review.
Cited by
-
A Case of Pheochromocytoma With Coagulation Necrosis Due to Hypertensive Crisis Aggravated by Contrast-Enhanced CT Scan and Negative 123I-Metaiodobenzylguanidine (MIBG) Scintigraphy.Cureus. 2024 Mar 25;16(3):e56878. doi: 10.7759/cureus.56878. eCollection 2024 Mar. Cureus. 2024. PMID: 38659567 Free PMC article.
-
Pheochromocytoma manifesting as cortical blindness secondary to PRES with associated TMA: a case report and literature review.BMC Endocr Disord. 2022 Aug 15;22(1):205. doi: 10.1186/s12902-022-01109-0. BMC Endocr Disord. 2022. PMID: 35971105 Free PMC article. Review.
-
A Case of 123I-Metaiodobenzylguanidine Scintigraphy-Negative Pheochromocytoma with a Tumor-Developing Mutation in the RET Gene.J Clin Med. 2022 Aug 8;11(15):4624. doi: 10.3390/jcm11154624. J Clin Med. 2022. PMID: 35956242 Free PMC article.
-
The good, the bad, and the ugly: uncommon CT appearances of pheochromocytoma.Abdom Radiol (NY). 2022 Apr;47(4):1406-1413. doi: 10.1007/s00261-022-03447-y. Epub 2022 Feb 25. Abdom Radiol (NY). 2022. PMID: 35212806 Review.
-
Imaging pheochromocytoma in small animals: preclinical models to improve diagnosis and treatment.EJNMMI Res. 2021 Dec 11;11(1):121. doi: 10.1186/s13550-021-00855-x. EJNMMI Res. 2021. PMID: 34894301 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical